Acquired
acute demyelinating peripheral polyneuropathy is a general classification of pathologies that affect the peripheral nervous system. They are characterised by an autoimmune process directed towards myelin. Clinically they are characterised by progressive weakness and mild sensory changes. Acute inflammatory demyelinating polyneuropathy is often referred to as Guillain-Barré syndrome (GBS). GBS includes acute inflammatory demyelinating polyradiculoneuropathy, acute motor axonal neuropathy, acute motor and sensory axonal neuropathy, Miller Fisher syndrome and acute pandysautonomia 1 . GBS is the major cause of acute non-traumatic paralysis in healthy people and it is caused by autoimmune response to viral agents (influenza, coxsackie, Epstein-Barr virus or cytomegalovirus) or bacterial infective organisms (Campylobacter jejuni, Mycoplasma pneumoniae).
GBS is clinically described as an ascending and progressive muscular weakness with areflexia, which progresses over a few days to a few weeks. A detailed history, the symptoms and the typical demyelinating electromyography pattern supports the diagnosis. Progressive involvement of respiratory muscles and autonomic instability coupled with a protracted and unpredictable recovery normally results in the need for intensive care unit management.
GBS has an incidence of about 1 in 100,000 and is found to occur in both genders and all ages. Despite medical treatment, GBS often remains a severe disease; 3 to 10% of patients die and 20% are still unable to walk after six months; in addition, many patients have pain and fatigue that can persist for months or years 2 .
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CASE HISTORY
We describe a case of a 78-year-old woman who presented with a two-day history of progressive general weakness and left facial nerve palsy, preceded by a flu-like illness lasting for one week. A provisional diagnosis of idiopathic facial paralysis (Bell's palsy) was made and the patient was discharged home after reassurance and no specific medications. One day later she returned with paralysis involving both sides of the face. During this hospitalisation she also developed severe pulmonary dysfunction and was transferred to the intensive care unit where she was intubated (despite the absence of significant abnormalities in the chest X-ray, arterial blood gases performed on passive oxygen therapy showed FiO 2 50%, Po 2 84 mmHg, Pco 2 36.6 mmHg) and mechanical lung ventilation was commenced.
Neurological examination revealed an absence of deep tendon reflexes, all other cranial nerves were intact and plantar reflexes were flexor throughout. Blood tests for full blood count, urea and electrolytes, serum angiotensin converting enzyme and a vasculitic screen were within normal limits. Blood culture was negative. No paraproteins were detected on serum protein electrophoresis. Cranial tomography was normal. There was characteristic slowing of conduction in peripheral nerves with axonal involvement shown on electromyography. Cerebrospinal fluid (CSF) examination showed 7 leucocytes/mm 3 (100% lymphocytes), a protein level of 0.29 g/l (normal range: 0.020 to 0.045 g/l), an albumin level of 0.172 g/l (serum albumin was 2.4 g/l) and the CSF/serum albumin index increasing.
GBS was diagnosed based on the patient history and typical CSF findings. In 1983 she had suffered GBS and was successfully treated with PE; her brother had also presented with GBS after a flu vaccination at the age of 78 years, with a good response to PE. After neurological advice, a five-day course of daily IVIg (0.4 g/kg/day) was commenced without benefit but with a progressive clinical deterioration. Seven days after completion of IVIg treatment, PE was started with an exchange of about three litres of plasma every day for three days and every second day on two occasions (a total of five PE were performed). A gradual improvement of respiratory function and peripheral strength were observed after the first PE. Mechanical ventilation was weaned and she was extubated on the eighth day and she started to walk with assistance.
DISCUSSION
PE was the first treatment in GBS proven to be superior to supportive treatment alone. It reduces the time to independent locomotion by approximately one month when applied within the first two weeks of disease 6, 7 . The first randomised controlled trial of the use of IVIg was published in 1992 and showed that IVIg is as effective as PE 4 . Since the publication of these results, IVIg in a regimen of 0.4 g/kg bodyweight daily for five consecutive days, has replaced PE as the preferred treatment in many centres, mainly because of its greater convenience and availability.
Is there any other evidence showing greater or less benefit from one or the other treatment? The Cochrane review on the use of IVIg in GBS contained four trials: no difference was found between IVIg and PE with respect to the improvement in disability grade after four weeks, the duration of mechanical ventilation, mortality or residual disability 8 . The combination of PE followed by IVIg is not significantly better than PE or IVIg alone 4 . A study in a small series of patients investigated the effect of a second course of IVIg in severe unresponsive patients with GBS. This uncontrolled study suggested that a repeated course of IVIg could be effective 9 .
The use of PE after IVIg treatment has received little attention; according to some authors, PE after IVIg is not advised because PE would probably wash out the IVIg previously administered 2 . On the other hand, a retrospective review of 10 patients with GBS showed that three patients improved with PE after a failing IVIg treatment, and that all these patients had axonal involvement on electromyogram 10 . A further report describes a 25-year-old male patient with GBS who, despite the IVIg infusion, manifested a rapid disease progression and obtained a gradual improvement of respiratory function and mobility only after six weeks of PE treatment 11 . Furthermore severe familial and recurrent forms of GBS, as in the case presented, seem to present with more dramatic symptoms which made them responsive to PE but not to IVIg 12, 13 .
